While Lineage has made significant progress with its OpRegen program and secured important partnerships, financial challenges persist with a decrease in revenue and a significant net loss. The advancements in clinical trials and partnerships offer promising long-term potential, but financial metrics present short-term challenges.

Company Guidance

During the Lineage Cell Therapeutics Third Quarter 2025 Conference Call, Brian Culley, the CEO, provided a comprehensive update on several strategic goals and the progress of their lead program, OpRegen. A key highlight was the expansion of the GAlette study by Genentech, which has opened eight new clinical sites in the past six months, totaling 15 locations, compared to just one in 2024. This expansion is seen as a positive indicator for the program. Culley mentioned that since the GAlette study began, Genentech reported data from the Lineage Phase I/IIa trial showing improvements in retinal structure and visual acuity, with an acceptable safety profile. The company also achieved a partnership with William Demant Invest A/S, which is expected to fund up to $12 million for the ReSonance program. Additionally, Lineage aims to secure a CIRM CLIN2 grant that could offset up to $7 million of costs for the ongoing OPC1 study for spinal cord injury. Financially, Lineage reported a cash position of $40.5 million, expected to fund operations into Q2 of 2027, and they are pursuing other funding sources, including potential milestone payments under the Roche-Genentech collaboration.

OpRegen Clinical Advancements

OpRegen has made significant progress with Genentech opening 8 new clinical sites in the last 6 months, totaling 15 sites. This expansion is a positive sign, supported by promising 36-month analyses showing improvements in retinal structure and visual acuity for patients.

Partnership with William Demant Invest A/S

Lineage secured a partnership with William Demant Invest A/S, expected to fund up to $12 million for the ReSonance program, demonstrating the platform's capability to attract external funding and collaboration.

Cash Runway Extension

Lineage's cash position of $40.5 million is expected to support operations into Q2 2027, extended by one quarter due to the William Demant partnership.

Potential $37 Million Warrant Capital

Lineage may receive approximately $37 million of warrant capital if Roche and Genentech advance OpRegen into a clinical trial with a comparator arm.

Lineage Therap (LCTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LCTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 05, 2026	2025 (Q4)	-0.05 / -	-0.02	―	―	―
Nov 06, 2025	2025 (Q3)	-0.03 / -0.13	-0.02	-550.00% (-0.11)	―
Aug 12, 2025	2025 (Q2)	-0.03 / -0.13	-0.03	-333.33% (-0.10)	―
May 13, 2025	2025 (Q1)	-0.03 / -0.02	-0.04	50.00% (+0.02)	―
Mar 10, 2025	2024 (Q4)	-0.03 / -0.02	-0.03	33.33% (<+0.01)	―
Nov 14, 2024	2024 (Q3)	-0.04 / -0.02	-0.04	50.00% (+0.02)	―
Aug 08, 2024	2024 (Q2)	-0.04 / -0.03	-0.03	0.00% (0.00)	―
May 09, 2024	2024 (Q1)	-0.04 / -0.04	-0.03	-33.33% (-0.01)	―
Mar 07, 2024	2023 (Q4)	-0.04 / -0.03	-0.03	0.00% (0.00)	―
Nov 09, 2023	2023 (Q3)	-0.04 / -0.04	-0.04	0.00% (0.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LCTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	$1.73	$1.76	+1.73%
Aug 12, 2025	$1.01	$1.03	+1.98%
May 13, 2025	$0.47	$0.46	-2.13%
Mar 10, 2025	$0.53	$0.53	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lineage Cell Therapeutics, Inc. (LCTX) report earnings?

Lineage Cell Therapeutics, Inc. (LCTX) is schdueled to report earning on Mar 05, 2026, After Close (Confirmed).

What is Lineage Cell Therapeutics, Inc. (LCTX) earnings time?

Lineage Cell Therapeutics, Inc. (LCTX) earnings time is at Mar 05, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LCTX EPS forecast?

LCTX EPS forecast for the fiscal quarter 2025 (Q4) is -0.05.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing